Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17570831
Hall KJ, Jones ML, Poole AW (2007) Coincident regulation of PKCdelta in human platelets by phosphorylation of Tyr311 and Tyr565 and phospholipase C signalling. Biochem J 406, 501-9 17570831
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y52-p - PKCD (human)
Modsite: VQKKPtMyPEWKSTF SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y52‑p, PKCD iso2 (human): Y52‑p, PKCD (mouse): Y52‑p, PKCD iso2 (mouse): Y52‑p, PKCD (rat): Y52‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  platelet-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
collagen no change compared to control
thrombin no change compared to control
PAR1-activating_peptide no change compared to control
PAR4-activating_peptide no change compared to control

Y155-p - PKCD (human)
Modsite: IKQAKIHyIKNHEFI SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y155‑p, PKCD iso2 (human): Y155‑p, PKCD (mouse): Y155‑p, PKCD iso2 (mouse): Y155‑p, PKCD (rat): Y155‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  platelet-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
collagen no change compared to control
thrombin no change compared to control
PAR1-activating_peptide no change compared to control
PAR4-activating_peptide no change compared to control

Y313-p - PKCD (human)
Modsite: ssEPVGIyQGFEKkT SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y313‑p, PKCD iso2 (human): Y313‑p, PKCD (mouse): Y311‑p, PKCD iso2 (mouse): Y311‑p, PKCD (rat): Y311‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  platelet-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PTP1B (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
PP1 thrombin inhibit treatment-induced increase
PP2 thrombin inhibit treatment-induced increase
PP3 thrombin no effect upon treatment-induced increase
U73122 thrombin inhibit treatment-induced increase
piceatannol thrombin no effect upon treatment-induced increase
LFM-A13 thrombin no effect upon treatment-induced increase
collagen increase
PAR1-activating_peptide increase
PAR4-activating_peptide increase
phorbol_ester increase
PP1 phorbol_ester inhibit treatment-induced increase
PP2 phorbol_ester inhibit treatment-induced increase
PP3 phorbol_ester no effect upon treatment-induced increase
U73122 phorbol_ester no effect upon treatment-induced increase
piceatannol phorbol_ester no effect upon treatment-induced increase
LFM-A13 phorbol_ester no effect upon treatment-induced increase

Y334-p - PKCD (human)
Modsite: MQDNsGtyGkIWEGs SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y334‑p, PKCD iso2 (human): Y365‑p, PKCD (mouse): Y332‑p, PKCD iso2 (mouse): Y358‑p, PKCD (rat): Y332‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  platelet-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
collagen no change compared to control
thrombin no change compared to control
PAR1-activating_peptide no change compared to control
PAR4-activating_peptide no change compared to control

T507-p - PKCD (human)
Modsite: FGEsRAstFCGtPDy SwissProt Entrez-Gene
Orthologous residues
PKCD (human): T507‑p, PKCD iso2 (human): T538‑p, PKCD (mouse): T505‑p, PKCD iso2 (mouse): T531‑p, PKCD (rat): T505‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  platelet-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
PP1 thrombin inhibit treatment-induced increase
U73122 thrombin inhibit treatment-induced increase
phorbol_ester increase

Y525-p - PKCD (human)
Modsite: EILQGLKyTFSVDWW SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y525‑p, PKCD iso2 (human): Y556‑p, PKCD (mouse): Y523‑p, PKCD iso2 (mouse): Y549‑p, PKCD (rat): Y523‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  platelet-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate increase
collagen no change compared to control
thrombin no change compared to control
PAR1-activating_peptide no change compared to control
PAR4-activating_peptide no change compared to control

Y567-p - PKCD (human)
Modsite: IRVDTPHyPRWITKE SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y567‑p, PKCD iso2 (human): Y598‑p, PKCD (mouse): Y565‑p, PKCD iso2 (mouse): Y591‑p, PKCD (rat): Y565‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  platelet-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PTP1B (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
thrombin increase
PP1 thrombin inhibit treatment-induced increase
PP2 thrombin inhibit treatment-induced increase
PP3 thrombin no effect upon treatment-induced increase
U73122 thrombin inhibit treatment-induced increase
piceatannol thrombin no effect upon treatment-induced increase
LFM-A13 thrombin no effect upon treatment-induced increase
collagen increase
PAR1-activating_peptide increase
PAR4-activating_peptide increase
phorbol_ester increase
PP1 phorbol_ester inhibit treatment-induced increase
PP2 phorbol_ester inhibit treatment-induced increase
PP3 phorbol_ester no effect upon treatment-induced increase
U73122 phorbol_ester no effect upon treatment-induced increase
piceatannol phorbol_ester no effect upon treatment-induced increase
LFM-A13 phorbol_ester no effect upon treatment-induced increase

Y419-p - Src (human)
Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  platelet-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U73122 no change compared to control
PP1 decrease
thrombin increase
U73122 thrombin inhibit treatment-induced increase
PP1 thrombin inhibit treatment-induced increase
phorbol_ester no change compared to control